Celgene Gross Profit 2006-2019 | CELG

Celgene annual/quarterly gross profit history and growth rate from 2006 to 2019. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Celgene gross profit for the quarter ending March 31, 2019 was $3.885B, a 14.16% increase year-over-year.
  • Celgene gross profit for the twelve months ending March 31, 2019 was $15.176B, a 15.88% increase year-over-year.
  • Celgene annual gross profit for 2018 was $14.694B, a 17.16% increase from 2017.
  • Celgene annual gross profit for 2017 was $12.542B, a 16.23% increase from 2016.
  • Celgene annual gross profit for 2016 was $10.791B, a 22.13% increase from 2015.
Celgene Annual Gross Profit
(Millions of US $)
2018 $14,694
2017 $12,542
2016 $10,791
2015 $8,836
2014 $7,285
2013 $6,154
2012 $5,208
2011 $4,416
2010 $3,319
2009 $2,474
2008 $1,997
2007 $1,276
2006 $773
2005 $456
Celgene Quarterly Gross Profit
(Millions of US $)
Q1 2019 $3,885
Q4 2018 $3,868
Q3 2018 $3,735
Q2 2018 $3,688
Q1 2018 $3,403
Q4 2017 $3,364
Q3 2017 $3,169
Q2 2017 $3,160
Q1 2017 $2,849
Q4 2016 $2,867
Q3 2016 $2,875
Q2 2016 $2,643
Q1 2016 $2,406
Q4 2015 $2,458
Q3 2015 $2,224
Q2 2015 $2,177
Q1 2015 $1,977
Q4 2014 $1,982
Q3 2014 $1,885
Q2 2014 $1,774
Q1 2014 $1,644
Q4 2013 $1,663
Q3 2013 $1,588
Q2 2013 $1,518
Q1 2013 $1,384
Q4 2012 $1,367
Q3 2012 $1,345
Q2 2012 $1,295
Q1 2012 $1,201
Q4 2011 $1,206
Q3 2011 $1,155
Q2 2011 $1,057
Q1 2011 $998
Q4 2010 $959
Q3 2010 $847
Q2 2010 $785
Q1 2010 $729
Q4 2009 $712
Q3 2009 $643
Q2 2009 $578
Q1 2009 $541
Q4 2008 $560
Q3 2008 $522
Q2 2008 $496
Q1 2008 $418
Q4 2007 $369
Q3 2007 $316
Q2 2007 $319
Q1 2007 $271
Q4 2006 $240
Q3 2006 $211
Q2 2006 $170
Q1 2006 $152
Q4 2005 $123
Q3 2005 $106
Q2 2005 $128
Q1 2005 $100
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $64.835B $15.281B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $106.696B 12.06
Gilead Sciences (GILD) United States $84.475B 10.26
Vertex Pharmaceuticals (VRTX) United States $45.024B 54.42
Biogen (BIIB) United States $44.871B 8.52
Illumina (ILMN) United States $44.842B 51.97
CSL (CSLLY) Australia $34.985B 0.00
Regeneron Pharmaceuticals (REGN) United States $31.970B 15.03
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.092B 15.33
Incyte (INCY) United States $17.177B 69.65
BioMarin Pharmaceutical (BMRN) United States $14.854B 0.00
Exact Sciences (EXAS) United States $14.834B 0.00
SINO PHARMACEUT (SBMFF) China $13.649B 0.00
Sarepta Therapeutics (SRPT) United States $11.575B 0.00
Genmab (GNMSF) Denmark $11.320B 57.55
Array BioPharma (ARRY) United States $10.411B 0.00
Seattle Genetics (SGEN) United States $10.289B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.950B 29.40
Bio-Techne Corp (TECH) United States $7.927B 54.08
Alnylam Pharmaceuticals (ALNY) United States $7.622B 0.00
Guardant Health (GH) United States $7.527B 0.00
Galapagos (GLPG) Belgium $7.468B 0.00
Bluebird Bio (BLUE) United States $7.312B 0.00
Amarin (AMRN) Ireland $7.239B 0.00
Exelixis (EXEL) United States $6.331B 16.14
BeiGene (BGNE) Cayman Islands $5.723B 0.00
Ascendis Pharma (ASND) Denmark $4.747B 0.00
Moderna (MRNA) United States $4.672B 0.00
Blueprint Medicines (BPMC) United States $4.641B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.479B 0.00
Horizon Pharma Public (HZNP) Ireland $4.337B 11.17
Repligen (RGEN) United States $4.014B 100.00
ACADIA Pharmaceuticals (ACAD) United States $3.926B 0.00
Mirati Therapeutics (MRTX) United States $3.811B 0.00
Spark Therapeutics (ONCE) United States $3.766B 0.00
China Biologic Products (CBPO) China $3.677B 23.35
Alkermes (ALKS) Ireland $3.535B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.365B 0.00
MorphoSys AG (MOR) Germany $3.223B 0.00
Arena Pharmaceuticals (ARNA) United States $3.048B 6.19
Amicus Therapeutics (FOLD) United States $2.858B 0.00
Immunomedics (IMMU) United States $2.810B 0.00
Medicines (MDCO) United States $2.716B 0.00
UniQure (QURE) Netherlands $2.658B 0.00
Reata Pharmaceuticals (RETA) United States $2.612B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.598B 0.00
Halozyme Therapeutics (HALO) United States $2.413B 0.00
Akcea Therapeutics (AKCA) United States $2.351B 0.00
MyoKardia (MYOK) United States $2.340B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.338B 0.00
Ligand Pharmaceuticals (LGND) United States $2.282B 18.90
Emergent Biosolutions (EBS) United States $2.223B 19.31
Acceleron Pharma (XLRN) United States $2.153B 0.00
Zai Lab (ZLAB) China $2.112B 0.00
NeoGenomics (NEO) United States $2.112B 138.25
Genomic Health (GHDX) United States $2.086B 44.31
Intercept Pharmaceuticals (ICPT) United States $2.076B 0.00
Denali Therapeutics (DNLI) United States $1.911B 0.00
Myriad Genetics (MYGN) United States $1.887B 18.77
Insmed (INSM) United States $1.765B 0.00
REGENXBIO (RGNX) United States $1.740B 0.00
Cambrex (CBM) United States $1.485B 18.78
AnaptysBio (ANAB) United States $1.474B 0.00
Innoviva (INVA) United States $1.432B 3.96
Fate Therapeutics (FATE) United States $1.404B 0.00
RA PHARMCTL INC (RARX) United States $1.399B 0.00
Sangamo Therapeutics (SGMO) United States $1.352B 0.00
Athenex (ATNX) United States $1.340B 0.00
Coherus BioSciences (CHRS) United States $1.333B 0.00
Alector (ALEC) United States $1.276B 0.00
Epizyme (EPZM) United States $1.246B 0.00
Editas Medicine (EDIT) United States $1.223B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.165B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.078B 0.00
Codexis (CDXS) United States $1.037B 0.00
ANI Pharmaceuticals (ANIP) United States $0.980B 17.39
Dicerna Pharmaceuticals (DRNA) United States $0.970B 0.00
Cara Therapeutics (CARA) United States $0.965B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.956B 0.00
Adverum Biotechnologies (ADVM) United States $0.955B 0.00
Zymeworks (ZYME) Canada $0.940B 0.00
Principia Biopharma (PRNB) United States $0.936B 0.00
Twist Bioscience (TWST) United States $0.927B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.921B 0.00
WAVE Life Sciences (WVE) Singapore $0.899B 0.00
Retrophin (RTRX) United States $0.893B 0.00
Vericel (VCEL) United States $0.871B 0.00
Arvinas (ARVN) United States $0.808B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.802B 0.00
Intellia Therapeutics (NTLA) United States $0.759B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.723B 34.15
Clovis Oncology (CLVS) United States $0.702B 0.00
Zealand Pharma (ZEAL) Denmark $0.683B 7.99
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Precision BioSciences (DTIL) United States $0.678B 0.00
Cellectis S.A (CLLS) France $0.673B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.659B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.643B 0.00
Cytokineticsorporated (CYTK) United States $0.637B 0.00
DBV Technologies S.A (DBVT) France $0.628B 0.00
Heska (HSKA) United States $0.626B 64.10
Intra-Cellular Therapies (ITCI) United States $0.617B 0.00
Stemline Therapeutics (STML) United States $0.577B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.575B 0.00
Anika Therapeutics (ANIK) United States $0.569B 19.44
Revance Therapeutics (RVNC) United States $0.553B 0.00
MiMedx (MDXG) United States $0.544B 0.00
CytomX Therapeutics (CTMX) United States $0.536B 0.00
Pharming Group (PHGUF) Netherlands $0.492B 0.00
UROGEN PHARMA (URGN) United States $0.454B 0.00
Mesoblast (MESO) Australia $0.452B 0.00
Puma Biotechnology (PBYI) United States $0.450B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
PHARMA MAR SA (PHMMF) Spain $0.436B 0.00
Gritstone Oncology (GRTS) United States $0.397B 0.00
Scholar Rock Holding (SRRK) United States $0.388B 0.00
Prothena (PRTA) Ireland $0.386B 0.00
Biofrontera AG (BFRA) Germany $0.385B 0.00
PDL BioPharma (PDLI) United States $0.375B 8.94
Syros Pharmaceuticals (SYRS) United States $0.371B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
AC Immune SA (ACIU) Switzerland $0.365B 23.48
BioDelivery Sciences (BDSI) United States $0.364B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.361B 0.00
Agenus (AGEN) United States $0.361B 0.00
Arcus Biosciences (RCUS) United States $0.361B 0.00
Bellus Health (BLUSF) Canada $0.360B 0.00
Prometic Life Sciences (PFSCD) Canada $0.355B 0.00
Merus (MRUS) Netherlands $0.353B 0.00
Theratechnologies (THERF) Canada $0.351B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.347B 0.00
Albireo Pharma (ALBO) United States $0.342B 0.00
Avid Bioservices (CDMO) United States $0.342B 0.00
Senesco Technologies (ELOX) United States $0.339B 0.00
Starpharma Holdings (SPHRY) Australia $0.336B 0.00
Acorda Therapeutics (ACOR) United States $0.319B 5.61
Kadmon Holdings (KDMN) United States $0.316B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.313B 0.00
Protagonist Therapeutics (PTGX) United States $0.310B 0.00
Sorrento Therapeutics (SRNE) United States $0.308B 0.00
Kindred Biosciences (KIN) United States $0.307B 0.00
Inovio Pharmaceuticals (INO) United States $0.293B 0.00
PHASEBIO PHARMA (PHAS) United States $0.275B 0.00
Cellular Biomedicine (CBMG) United States $0.268B 0.00
Sutro Biopharma (STRO) United States $0.267B 0.00
Dynavax Technologies (DVAX) United States $0.262B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.262B 0.00
Geron (GERN) United States $0.250B 0.00
Athersys (ATHX) United States $0.246B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.244B 0.00
ChromaDex (CDXC) United States $0.242B 0.00
Kamada (KMDA) Israel $0.236B 9.17
ADMA Biologics Inc (ADMA) United States $0.234B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.213B 0.00
Cerecor (CERC) United States $0.213B 0.00
Synlogic (SYBX) United States $0.206B 0.00
Abeona Therapeutics (ABEO) United States $0.206B 0.00
MannKind (MNKD) United States $0.205B 0.00
Five Prime Therapeutics (FPRX) United States $0.204B 0.00
Affimed (AFMD) Germany $0.195B 0.00
POXEL SA FRANCE (PXXLF) $0.194B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.193B 0.00
Mersana Therapeutics (MRSN) United States $0.189B 0.00
Enzo Biochem (ENZ) United States $0.187B 0.00
OSMOTICA PHARM (OSMT) United States $0.186B 0.00
Compugen (CGEN) Israel $0.185B 0.00
Spero Therapeutics (SPRO) United States $0.183B 0.00
Arsanis (XFOR) United States $0.182B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.163B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.161B 0.00
Strongbridge Biopharma (SBBP) United States $0.158B 9.13
XOMA (XOMA) United States $0.152B 0.00
Dyadic (DYAI) United States $0.151B 0.00
Liquidia Technologies (LQDA) United States $0.147B 0.00
OvaScience (MLND) United States $0.143B 0.00
Celyad SA (CYAD) Belgium $0.141B 0.00
TOCAGEN INC (TOCA) United States $0.141B 0.00
Cue Biopharma (CUE) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Arbutus Biopharma (ABUS) Canada $0.136B 0.00
Northwest Biotherapeutics (NWBO) United States $0.135B 0.00
Aptinyx (APTX) United States $0.126B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.123B 0.00
Aduro Biotech (ADRO) United States $0.119B 0.00
Seres Therapeutics (MCRB) United States $0.119B 0.00
Alcobra (ARCT) United States $0.119B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.118B 0.00
Menlo Therapeutics (MNLO) United States $0.118B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.115B 0.00
Novavax (NVAX) United States $0.115B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.113B 0.00
Verastem (VSTM) United States $0.112B 0.00
NantKwest (NK) United States $0.110B 0.00
Checkpoint Therapeutics (CKPT) United States $0.105B 0.00
Catalyst Biosciences (CBIO) United States $0.102B 0.00
Fortress Biotech (FBIO) United States $0.100B 0.00
Trevena (TRVN) United States $0.097B 0.00
SESEN BIO, INC (SESN) United States $0.093B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.086B 0.00
VBI Vaccines (VBIV) United States $0.083B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.082B 0.00
Pluristem Therapeutics (PSTI) Israel $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.079B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.079B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.076B 0.00
AquaBounty Technologies (AQB) United States $0.075B 0.00
Curis (CRIS) United States $0.075B 0.00
Selecta Biosciences (SELB) United States $0.074B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
VTv Therapeutics (VTVT) United States $0.069B 0.00
Unum Therapeutics (UMRX) United States $0.068B 0.00
Organovo Holdings (ONVO) United States $0.067B 0.00
Applied Genetic Technologies (AGTC) United States $0.067B 36.70
ARAVIVE, INC (ARAV) United States $0.067B 0.00
Orgenesis (ORGS) United States $0.065B 0.00
Signal Genetics (MGEN) United States $0.063B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
Prima BioMed (IMMP) Australia $0.059B 0.00
Invo BioScience (IVOB) United States $0.056B 0.00
AIT Therapeutics (AITB) United States $0.055B 0.00
Oncobiologics (OTLK) United States $0.055B 0.00
DiaMedica Therapeutics (DMAC) United States $0.055B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Proteostasis Therapeutics (PTI) United States $0.051B 0.00